Pharyngula

We’re coming up on Burzynski’s 70th birthday — it’s a bit ironic that the man responsible for so many shattered hopes has had such a long life himself — and there is a plan to remind him of the grief he has caused.

Burzynski, if you’ve forgotten, is the guy who claims to have a cancer treatment called antineoplastons, a small set of compounds isolated from urine that he injects at high dosages into cancer patients. These drugs have not had their efficacy demonstrated, but Burzynski keeps cycling through clinical trials, taking the preliminary steps to demonstrating scientific utility, but never quite advancing the results to the point where they can demonstrate significance. He’s cunning that way; by constantly playing the game and running the mill of phase II trials, he puts up a pretense of scientific seriousness, but he never goes further, where his snake oil would be shown to be ineffective. Burzynski’s claims are total nonsense.

What he does do is promise remarkable results, and bilk people out of buckets of money — tens to hundreds of thousands of dollars gouged out of desperate patients — and then go home to his 6 million dollar, gated, wooded estate. Crime does pay, and it pays well. This fraud is living in luxury while his patients pour money into his clinic in the frantic hope that maybe the sciencey-sounding jargon of his well-practiced spiel means they’ll really get a cure.

They don’t. You can read the accounts of the other Burzynski patients — the ones he’d rather you didn’t know about. The Burzynski clinic is a place you go to die, and pay extravagantly for the privilege.

Right now, he and his propagandists are claiming to be doing “Personalized Gene-Targeted Cancer Therapy”, and touting the relevance of information from the human genome project for their treatment. But they’re still just injecting people with concentrated extracts of human urine! The lies are simply outrageous, but nothing seems to hinder him from making them.

Burzynski has plenty of lawyers and has fended off many attempts to shut down his quackery, so what can you do? We can raise money for a legitimate cancer center, St Jude’s Children’s Hospital, and challenge him on his birthday to match our contributions. The goal is to raise at least $30,000, an amount that is minuscule compared to the millions he has bilked from the sick and dying, but the point is to shame the man, and maybe get some money redirected to legitimate hospitals, where it can do some real good.

Read the latest on Burzynski from Science-Based Medicine, and get angry/inspired. Every penny raised does double-duty, making both a contribution to real medical work, and helping to raise attention about this shameless quack.

Donate!

Comments

  1. #1 Dale Husband
    January 6, 2013

    There are laws against fraud, we just need to enforce them.

  2. #2 rjblaskiewicz
    Wisconsin
    January 7, 2013

    Thanks, PZ. In a bit of bad news, another one of his former patients died today. They were told that a tumor that had outgrown its blood supply was dying off on the inside because of the bogus treatment. Unconscionable. It was poor Amelia Saunders, who was a beautiful sweetie who deserved a better doctor.

  3. #3 idaridgrner
    Idaho
    January 7, 2013

    No worse than the hoax being perpetrated by the cancer industry. There is no cure only treatment. Check it out 98 % of those treated die from the treatment as it is cancer causing.

  4. #4 novalox
    January 7, 2013

    @idaridgrner
    [citation needed] for you unfounded claim.

  5. #5 Harvey
    January 7, 2013

    I have been “treating” cancer of the head and neck (I am an Otolaryngologist) for over forty years. 70% of them have been “cured” (survived at least five years after completion of treatment with no evidence of persistant disease), Many of these patients, in recent years, have had chemotherapy, either as the sole treatment or in combination with surgery. To claim that htere are no cures is not onky false, but may actally prevent some patients who could benefit from such treatment from getting it, In this regard, it is just as unconscionable for anyone to “claim” that there is a “cancer industry” as it is for a very few unscrupulous people to profit from totally useless false treatments.

  6. #6 jane
    January 7, 2013

    You might also make the point that there is no such thing as a legitimate clinical trial where the patients must PAY to participate.

  7. #7 sufyan khan
    www.infoaw.com
    January 8, 2013
  8. #8 Orac
    January 8, 2013

    No worse than the hoax being perpetrated by the cancer industry. There is no cure only treatment. Check it out 98 % of those treated die from the treatment as it is cancer causing.

    Uh, no. Not true. But do provide a citation; it’ll be amusing, and chances are I’ve already seen it.

  9. #9 Anthony Stout
    January 9, 2013

    Are you serious? Have you spoken to any survivors? Have you heard of it actually working? I feel that telling the parents of a child who has no way of surviving a brain tumor, to just have some chemo/radiation, which is pure poison, and has never ever cured or slowed down the growth of a DIPG tumor,on top of dealing with the pain of the tumor is madness! Oh and by the way we will bill you 300+thousand for this “clinical ” trial that has never worked! On the other hand, here’s a Dr whom you say is a quack but yet you’ve never spoke to him, never talked to a “survivor” probably never been to his clinic! Why is he a quack, how is he shattering the hopes of people when Dr’s and cancer centers, including St.Judes, do the same thing!!!?? For the record, he never promises he will and can cure! I know this.
    Please let me know where you are getting this info from so I can read or see for myself.

  10. #10 Jason
    St louis
    January 10, 2013

    What an idiot you are. If his drug has worked on 1 person it’s a success. Sure there are counts from people it hasn’t worked in. But his therapy has better results than normal chemotherapy. Everyone should have their own choice on treatment. SY what you want, facts don’t lie and his numbers tell the truth. If I get cancer I’m going to choose treatment with the BETTER STATISTICS

  11. #11 Jessica
    Oregon
    January 10, 2013

    If anything, the National Cancer Insistution is the real fruad here. I’ve seen more progress from Burzynski than them.

  12. #12 Jessica
    Oregon
    January 10, 2013

    Better*, i apologize. Maybe not more, but better.

  13. #13 Anthony Stout
    January 10, 2013

    I’m on here for one purpose only…..TO LET EVERYONE WHO THINKS LIKE THIS PZ GUY THINKS ABOUT BURZYNSKI. MY SON IS STILL HERE TWO YEARS LATER AND I KNOW OF OTHERS WHO WERE DIAGNOSED IN THEIR CHILDHOOD WHO ARE NOW IN THEIR late 20′s WITH CHILDREN OF THEIR OWN!! IF BURZYNSKI HAD THE FUNDING LIKE ALL OF THESE OTHER INSTITUTES I CAN ONLY IMAGINE WHERE HIS TREATMENTS WOULD BE!! PLEASE BELIEVE ME WHEN I TELL YOU MY SON IS STILL HERE AND NEVER HAD A DAY OF CHEMO OR RADIATION IN HIS LIFE!! IHEARTNOAH.ORG PROOF SCIENTIFIC OR NOT HE IS ALIVE AND THE TUMOR HAS BEEN STABLE AND HAS NOT GROWN IN OVER A YEAR!!!
    BURZYNSKI IS THE TRUTH!!

  14. #14 Flo
    January 10, 2013

    I sincerely hope your son will be one of the few lucky ones that get better without proper treatments, I really do. But if he does get lucky, that doesn’t make Burzynski any less of a fraud. Personal anecdotes, while touching, do not replace statistics and empiricism.
    The mere fact that a couple of people here talk about cancer like it’s one singular entity with one particular rate of recoveries and deaths shows how ill informed these folks are.
    There are a number of cancer-types that we can actually heal in 80-90% of cases these days, especially types of leucaemia and lymphoma. Others, in the meantime, present a much larger challenge even today, some even practically being a death sentence.

  15. #15 FilipinoMDstudent
    January 13, 2013

    LOL @Burzynski supporters here.

    Burzynski is a quack because he is promoting an unproven treatment (yes, having stories of cured individuals does not prove it works). Furthermore, there is no excuse for charging thousands upon thousands of dollars for enrolling in a clinical trial. In reality, participants who enroll in a trial don’t have to pay anything, and are even going to be compensated for injuries they might sustain due to the clinical trial.

    If his antineoplastons do work, he should have published every single one of his clinical trials in respectable journals. But guess what: of the 61 trials he registered in clinicaltrials.gov, only 1 has been completed and the rest have either unknown status or have been withdrawn/terminated. This is a massive, massive case of publication bias.

  16. #16 Critical Thinker
    January 13, 2013

    @Anthony Stout:
    First, speaking in caps only adds to the sensationalism.

    And second, it is now impossible for you to prove that your anecdote wouldn’t have happened the same way without Burzynski’s “treatments”. You have to consider that some people can become “cured” of any given disease while taking a sugar pill, or praying to Xenu or Mickey Mouse — correlation is not causation.

    Empirical data is required.

  17. #17 Nathan
    January 13, 2013

    How many people have died under chemotherapy? How many have died BECAUSE of chemotherapy? What’s the average cost of conventional cancer treatment?
    Also… Regular drug trials are free because pharmceuticals have BILLIONS of dollars at their disposal.

  18. #18 FilipinoMDstudent
    January 13, 2013

    Nathan, you are asking the wrong questions. The better things to ask are these:

    1) What is the risk of dying of a specific cancer without any form of treatment?
    2) What is the risk of dying of a specific cancer under a specific treatment regimen?
    3) Is the risk of dying under this treatment greater than the risk of no treatment?

    Simply asking absolute numbers can create the illusion that treatment does not give any benefit. You have to weigh the potential benefits with the potential risks.

    So what if big pharma has “BILLIONS of dollars at their disposal”? If Burzynski doesn’t have money to conduct clinical trials (which I highly doubt since I think he’s filthy rich), then the correct option would be to NOT CONDUCT A CLINICAL TRIAL. It is grossly unethical to charge patients (hundreds of thousands of dollars, no less) who risk their lives to participate in medical research.

  19. #19 Didymus Judas Thomas
    At the Tu-Quack Center checking out what the uninformed masses are doing
    January 14, 2013

    Ho Hum !!! SRB has lots of lawyers? I thought Richard Jaffe was doing good as SRB’s attorney.
    I’ve been busy going after the alleged “Neutral” Net resource to spend much time here since the New Year started.
    Pointing out things like:
    “Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls,” “Japanese Journal of Clinical Oncology” (which can be reviewed in HTML or PDFs at pg. 5 of 9 & reference at pg. 9)
    “A 2008 medical review stated that Burzynski “discovered that peptides and hormones including butyric acid and phenylbutyrate when added to cancer cells results in their differentiation, converting them into normal cells again.” “In the solitary phase II study” of “Antineoplastons” [consisting of A10 (A10I) and AS2-1 injections], “the overall survival at 2 and 5 years was 39 and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma. Progression-free survival at 6 months was 39%. Complete response was achieved in 11%, partial response in 11%, stable disease in 39% and progressive disease in 39% of patients.” & based on
    “The Oncologist,” “Complementary and Alternative Therapies for Cancer” (which can be reviewed in HTML or PDFs at pg. 4 of 10 & references at pg. 7);
    “A 2004 Memorial Sloan-Kettering Cancer Center medical review stated that antineoplastons therapy “research at the Burzynski Institute was permitted under an Investigational New Drug permit. The group’s preliminary report from a single-arm phase II study of 12 patients showed a 50% response rate.”
    Burzynski’s work is still being referenced: 5/2011 BMC Chemical Biology, as References 4 & 31 & research has been published up to & including 10/2010 Journal of Radioanalytical and Nuclear Chemistry & that research has been done in Poland, Korea, Egypt, Japan, & China referred to Burzynski’s work 6/8/2012 in conjunction with the Department of Molecular Genetics and Microbiology, Shands Cancer Center, University of Florida, Gainesville, FL, USA & independent researchers in other countries verify Burzynski’s research; including Phase III Clinical Trials in breast cancer, NSCLC, & primary hematoma reported 6/2005 by China/Taiwan in the Chinese Journal of Clinical Oncology.

  20. #20 Kevin
    January 14, 2013

    @Didymus Judas Thomas:

    lol wut?

    I’m not sure what you were trying to say because it’s not great English- maybe it’s not your first language though, so I won’t dwell on that. More important is all this junk you threw up here seemingly with the intent of making it seem legit and official by using technical jargon and putting quotation marks around things and making reference to HTML and PDF and journals and such with no specifics whatsoever. Where did all this come from? What ARE these PDF and HTML links you say we can read this at?

    A lot of this is meaningless. Like, “A 2004 Memorial Sloan-Kettering Cancer Center medical review stated that antineoplastons therapy “research at the Burzynski Institute was permitted under an Investigational New Drug permit. The group’s preliminary report from a single-arm phase II study of 12 patients showed a 50% response rate.” So? No one said he’s not doing research (or more precisely, doing research in 2004). Please provide any legitimate links. Don’t copypasta a bunch of crap and expect us to be impressed.

  21. #21 Kevin
    January 14, 2013

    I dug around a bit. In Japanese Journal of Clinical Oncology, there is an article “Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls” that reviews Burzynksi along with everything from homeopathy to Tibetan yoga to shark cartilage as alternative treatments. That’s not necessarily much of an endorsement. And it also points out that clinical trials have not gotten far, as was mentioned by the original poster.

    Then I googled Journal of Radioanalytical and Nuclear Chemistry and found the 10/2010 issue. I did a search for “Burzynski” within the journal and it came back w/ zero results. Same for “antineoplastons.” In fact, it looks like the site is telling me those terms don’t appear in any issue of the journal, but I could be wrong.

  22. #22 Kevin
    January 14, 2013

    really wondering what the Tu-Quack Center is btw

  23. #23 Didymus Judas Thomas
    At the Tu-Quack Center - glad some people know what an Internet search engine is
    January 15, 2013

    I am not a fan of Orac’s web-site blocking / hold-up process. So I add spaces to prevent it.

    http:// jjco. oxfordjournals. org/content/38/8/512.full?sid=5c546408-071e-4148-abd3-6c295dd5c6d7

    http:// jjco. oxfordjournals. org/content/38/8/512.full.pdf?sid=f8e0a3cc-2912-40e5-a7c2-dbd6db4b3c1d

    http:// m. jjco. oxfordjournals. org/content/early/2008/08/05/jjco.hyn066.full.pdf#page=1

    http:// www. ncbi. nlm. nih. gov/m/pubmed/18682440

    http:// theoncologist. alphamedpress. org/content/9/1/80.full?sid=aeef6d69-bf46-4bd0-93b0-f259cd21d416

    http:// theoncologist. alphamedpress. org/content/9/1/80.full.pdf

    http:// www. oncocure. ca/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

    http:// www. ncbi. nlm. nih. gov/m/pubmed/14755017

    To those who are playing catch-up, SRB did not file patents in all countries. So for all the SRB money-grubbing claimants out there who don’t know, he did not file in the most populous country on the planet, where they have done phase III trials using human urine-based cancer treatment. Hello!!! Who is known for synthesizing human urine-based cancer treatment???

  24. #24 Didymus Judas Thomas
    At the Tu-Quack Center for Piss-Poor Peer-Reviewed Portals
    January 16, 2013

    Radioanalytical and Nuclear Chemistry, 2010:

    http:// link. springer. com/article/10.1007%2Fs10967-010-0633-2

    http:// link. springer. com/article/10.1007%2Fs10967-010-0633-2?LI=true

    http:// link. springer. com/article/10.1007/s10967-010-0633-2/fulltext.html

    http:// onlinelibrary. wiley. com/doi/10.1021/js960120y/abstract

  25. #25 Didymus Judas Thomas
    At the Tu-Quack Center established to rebut the Quack claimers
    January 16, 2013

    BMC Chemical Biology 5/2011 Research article: Chemical modification of L-glutamine to alpha-amino glutarimide on autoclaving facilitates Agrobacterium infection of host and non-host plants: A new use of a known compound
    http:// link. springer. com/article/10.1186/1472-6769-11-1/fulltext.html

    http:// link. springer. com/content/pdf/10.1186%2F1472-6769-11-1

  26. #26 Narad
    January 17, 2013

    BMC Chemical Biology 5/2011 Research article: Chemical modification of L-glutamine to alpha-amino glutarimide on autoclaving facilitates Agrobacterium infection of host and non-host plants: A new use of a known compound

    I take it that you are proposing that Burzynski is actually using his patients for transgenic drug production experiments. That should be a selling point.

  27. #27 Didymus Judas Thomas
    At the Tu-Quack Center Naradiology Room
    January 17, 2013

    Uhhh … NO. I am proposing what I originally posted:

    Burzynski’s work is still being referenced: 5/2011 BMC Chemical Biology, as References 4 & 31.

  28. #28 Aida
    January 17, 2013

    this article is pure junk. are you also paid by FDA?

  29. #29 Aida
    January 17, 2013

    this article defends some interests, it’s not informing people or helping them.

  30. #30 MarkL
    January 17, 2013

    @Aida

    this article is pure junk. are you also paid by FDA?

    The article is spot on. The factual content is accurate and the conclusions drawn from those facts are inescapable: Burzynski is a fraud, feathering his own nest from exploiting the misery and desperation of cancer victims and their families and friends. The man is a ghoul, and all the hissy fits of his supporters and the propaganda produced by his cohorts cannot disguise the facts.

    Only Stan “the brave maverick” himself can save his own reputation…………… by finishing maybe just ONE of the 60+ phase II trials he has started (and charged mightily for inclusion in) in the last 3 decades or more and publishing the results.

    Can you tell me why he hasn’t done this? No? I didn’t think so, because nor can any other Burzynski supporter. Nor can “the brave maverick” himself.

    No doubt IF you reply you will be tempted to sidetrack into attacking the FDA and “big pharma” instead of answering the question, or offering again the mish-mash of media puff-pieces, advertorials, in vitro studies, toxicology reports and abstracts of Burzynski presentations that normally pass for evidence in the cloud-cuckoo land that Alt-med/Big Pharma conspiracy theorists normally exist in, but please note that, for those of us for whom “because I said so” is not accepted as proof, the results of his phase II trials showing some level of efficacy exceeding current conventional treatment regimes will see him accepted as the genius you believe he is.

  31. #31 Didymus Judas Thomas
    At the Tu-Quack Center Liars Lair Library
    January 17, 2013

    Gee MarkL. If this Article is “spot on,” where is the back-up for:

    1. “Burzynski has plenty of lawyers”

    2. “Burzynski’s claims are total nonsense”

    Because I sure would like to know what “FACTS” you’re going to whip out to undermine the Japanese Phase II Clinical Trial & 2005 Chinese Phase III Clinical Trial.

    Just bring (your) “IT.”

  32. #32 MarkL
    January 18, 2013

    Diddums you troll, hiding out here because your pathetic copy/pasta salads were comprehesively torn to shreds over on Orac’s blog?

    Post the results for these Phase II and Phase III trials. You haven’t so far, all you have done (and yes I have checked the articles you have linked above) is exactly what I predicted in my previous post:

    ……. offering again the mish-mash of media puff-pieces, advertorials, in vitro studies, toxicology reports and abstracts of Burzynski presentations that normally pass for evidence in the cloud-cuckoo land that Alt-med/Big Pharma conspiracy theorists normally exist in……..

    You are long on argument, short on data. As usual!

  33. #33 Didymus Judas Thomas
    In the Tu-Quack Center Data Room
    January 18, 2013

    MarkLiar, so, no back-up for the lawyer statement? I didn’t think so!

    MarkPinocchio, too lazy to see I’ve posted on Orac’s newer blogposts? I thought so!!

    MarkLoser, too lazy to look up the Japanese Phase II Clinical Trial I already posted about on the Orac blog I was posting on previously, &/or do an Internet search like some of the other liars on this blog who have made factually inaccurate statements that I’ve caught them with their pants down under on? I thought so!!!

    8/2005 Chinese Journal of Clinical Oncology.
    Phase 3 clinical trials of cell differentiation agent-2 (CDA-2): [a urinary preparation, isolated from healthy human urine] Therapeutic efficacy on breast cancer, non-small cell lung cancer & primary hepatoma.

    Objective of study was to explore the effect of CDA-2, a selective inhibitor of abnormal methylation enzymes in cancer cells, on the therapeutic efficacy of cytotoxic chemotherapy.

    Advanced cancer patients, all of whom had previously undergone chemotherapy, were randomly divided into 2 groups

    1. receiving chemotherapy only as the control group, &

    2. receiving CDA-2 in addition to chemotherapy as the combination group.

    Therapeutic efficacies & toxic manifestations of the groups were compared based on WHO criteria.

    454 cancer patients enrolled in trials.

    a). 80 breast cancer
    b) 188 NSCLC
    c) 186 primary hepatoma

    378 completed treatments according to protocols.

    Overall effective rate of combination group was 2.6 fold of control group,

    a) 4.8 fold in the case of breast cancer
    b) 2.2 fold in the case of NSCLC
    c) 2.3 fold in the case of primary hepatoma

    Combination therapy appeared to work better for stage IV than stage III patients.

    CDA-2 did not contribute additional toxicity.

    Reduced toxic manifestations of chemotherapy, particularly regarding white blood cells, nausea & vomiting.

    Modulation of abnormal methylation enzymes by CDA-2 definitely helpful to supplement chemotherapy.

    Significantly increased therapeutic efficacy & reduced toxic manifestation of cytotoxic chemotherapy on breast cancer & NSCLC.
    http:// www. springerlink. com/content/w71l3l8575333n01

    http:// link. springer. com/article/10.1007%2FBF02819536

    http:// link. springer. com/content/pdf/10.1007%2FBF02819536

    http:// link. springer. com/article/10.1007%2FBF02819536?LI=true

    3 – 4/2003 – Phase II – Japan
    The preventive effect of antineoplaston AS2-1 on HCC (hepatocellular carcinoma) recurrence

    phase II clinical trail to clarify whether antineoplaston AS2-1 prolongs recurrence-free interval of HCC patients who undergo frequent treatments for recurrence.

    10 patients enrolled in trial
    at initial diagnosis
    2 in stage I
    6 in stage II
    1 in stage III
    1 in stage IV-B

    10 patients experienced 35 recurrence-free intervals.

    Recurrence-free intervals during AS2-1 administration were significantly longer than those without AS2-1

    (16.19+/-15.916 v. 5.05+/-2.897 months: p<0.01)

    Patients who experienced recurrence-free intervals with & without AS2-1 showed longer intervals during AS2-1 administration than those before & after AS2-1 administration

    (14.47+/-13.821 v. 5.07+/-2.989 v. 5.02+/-3.009 months: p<0.05)

    2 patients in stage I showed longer recurrence-free intervals than those in more advanced stages.

    AS2-1 prolonged recurrence-free interval between regional treatments & improved survival rate of patients.
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12579278

  34. #34 MarkL
    January 18, 2013

    @Diddums.

    You are a fraud too Diddums.

    Your Chinese trial is nothing to do with Antineoplastons, it is a trial of cytidine deaminase in combination with conventional chemo-therapy.

    The Phase II trial you mention is real, but you neglected to add that the conclusion of the trial was that AS2-1 can “not prevent recurrence of HCC”. Indeed the trial does not even attempt to show that this ANP can cure this cancer or any other .

    So tell me how this pertains to Burzynski’s claim that Antineoplastons cure cancer? You really are clutching at straws Diddums, 2/10. Really must try harder.

  35. #35 Patrick the Star
    January 19, 2013

    Life is short. If you cannot use it to attempt to help your fellowman, why use it slandering people who try?

  36. #36 The zoo visitor
    Singapore
    January 19, 2013

    First of all, I’ll admit that I enjoy reading quacks & their supporters blogs, it’s like visiting a medical school’s storage room: where various body sections and some weirdly mangled tissues or animals are floating in glass tubes full of formaldehyde. It’s a bit of fascination with mental perverse rationalization that we humans are capable of.

    Now to Patrick the Star: there is no statistical evidence that quacks including that Burzynski fellow are any more helping than a placebo.

  37. #37 MarkL
    January 19, 2013

    @Patrick

    Its libel, not slander, that you are thinking of. and a statement cannot be libellous if it is true.

    There is no more evidence to support his claims for antineoplastons than there is for pixie dust.

    Burzynski is a fraud. Reckon he is going to send Jaffe after me with a libel case?

  38. #38 Didymus Judas Thomas
    At the Tu-Quack Center MarkyLMark Liar Lair Library
    January 20, 2013

    MarkyLMark, you would actually be funny if it was about your looks!!

    “”You can fool all the people some of the time and some of the people all of the time, but you cannot fool all the people all the time.”
    .
    MarkyLMark, you unabashed LIAR.
    .
    Last year I showed what a LIAR you were on 12/3 & I see you’re continuing your tradition in the New Year.
    .
    Was that your New Year’s resolution; to continue to be a dissimulator??
    .
    I even put it in brackets for you on the previous post:
    .
    CDA-2: [a URINARY preparation, isolated from HEALTHY HUMAN URINE.]
    .
    Phase Ⅲ Clinical Trials of the
    .
    CELL DIFFERENTIATION AGENT-2 (CDA-2):
    .
    Therapeutic Efficacy on Breast Cancer, Non-Small Cell Lung Cancer and Primary Hepatoma
    .
    MarkyLMark, where the H-E-Double-Hockey-Sticks do you think they came up with “URINARY preparation, isolated from HEALTHY HUMAN URINE???”
    .
    Drug type: 2-CdA is an anti-cancer (“ANTINEPLASTIC” or “cytotoxic”) chemotherapy drug.
    http:// chemocare. com/chemotherapy/drug-info/2-cda.aspx
    .
    Let’s look at some of the references for that Phase 3 publication, shall we? (Since you didn’t.)
    .
    7. Liau MC, Lee SS, BURZYNSKI SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Intl J Exp Clin Chemother. 1989; 2: 187–199.
    (PDF-pg. 9 of 11)
    .
    23. Liau MC, BURZYNSKI SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res. 1986; 12 (Suppl. l): 77–86.
    (PDF-pg. 10 of 11)
    .
    32. Liau MC, Lee SS, BURZYNSKI SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by ANTINEOPLASTON A5. Intl J Tiss React 1990; 12 (Suppl. l): 27–36.
    (PDF-pg. 10 of 11)
    .
    35. Liau MC, Szopa M, BURZYNSKI, et al. Chemo-surveillance: a novel concept of natural defense mechanism against cancer. Drugs Exp Clin Res. 1987; 13: (Suppl. l): 77–82.
    (PDF-pg. 10 of 11)
    .
    http:// file. lw23. com/f/f0/f07/f074852c-64a4-4b03-8595-47a5e6609a3f.pdf
    (PDF – 11 pgs.)
    .
    [7] DNA DEMETHYLATION has gained momentum as a logical approach for cancer therapy [7-13]
    and as a consequence cancer cells were induced to undergo terminal DIFFERENTIATION through INDUCTION of DNA HYPOMETHYLATION. [ 71
    (PDF-2 references pg. 2 of 11)
    .
    [23] METHYLATION enzymes are altered in CANCER cells. CANCER cells generate a cancer-specific factor that becomes associated with MAT and SAHH. The association of the CANCER-specific factor changes the kinetic properties of MAT and SAHH and also the regulation of the ternary enzyme COMPLEX. [20-23]
    (PDF-pg. 2 of 11)
    .
    [32] CDA·- 2 is a perfect solution of the abnormal METHYLATION enzymes of CANCER cells. CDA·2 is purified from FRESH HUMAN URINE. CDA 一 2 contains DIFFERENTIATION inducers capable of selectively antagonizing the CANCER-specific factor of abnormal METHYLATION enzymes.【32]
    These multiple components work cooperatively to achieve a good CANCER therapy. Preclinical studies of CDA一2 have yielded results showing that abnormal METHYLATION enzymes could be effectively eliminated by CDA一2. [32】
    (PDF-2 references pg. 2 of 11)
    .
    [35] In addition it is comprised of anti—cachexia chemicals which can prevent CANCER patients from excreting too much endogenous anticancer metabolites such as those present in CDA一2. .[351
    (PDF-pg. 2 of 11)
    .
    And maybe we could look at some other CDA-2 references!!
    .
    12/17/2012 - CDA-2 - China
    CDA-2, a URINARY Preparation, Inhibits Lung Cancer Development through the Suppression of NF-kappaB Activation in Myeloid Cell
    CDA-2 (cell differentiation agent 2), a URINARY preparation, has potent anti- proliferative & pro-apoptotic properties in cancer cells. Here we demonstrate that CDA-2 & its main component PHENYLACETYLGLUTAMINE (PG) reduce the metastatic lung tumor growth, & increases survival time after inoculation with Lewis lung carcinoma (LLC) cells...
    .
    [Gee!! Where have we seen "PHENYLACETYLGLUTAMINE (PG)" before???]
    .
    National Cancer Institute, at the National Institutes of Health cancer . gov:
    .
    “AS2-5, which is PHENYLACETYLGLUTAMINE (PAG).”
    .
    “AS2-1, which is a 4:1 mixture of phenylacetic acid (PA) and PAG.” (PHENYLACETYLGLUTAMINE)
    .
    “Antineoplastons AS2-5 and AS2-1 are derived from A10. Antineoplaston AS2-5 is PAG, and AS2-1 is a 4:1 mixture of PA and PAG.” PHENYLACETYLGLUTAMINE)
    http:// www. cancer. gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page2
    2006 – CDA-II –
    4. Lin WC, Liao YC, Liau MC, Lii CK, Sheen LY (2006) Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol 44: 546–551.
    2008 – CDA-2 –
    6. Huang J, Yang M, Liu H, Jin J (2008) HUMAN URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin 29: 951–964.
    http:// www. plosone. org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117
    .
    .
    6/8/2012 – China / USA
    http:// www. ncbi. nlm. nih. gov/m/pubmed/22627135
    PloS one
    Biochemical and Biophysical Research Communications, Elsevier
    DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation.
    CDA-II (cell differentiation agent II), isolated from HEALTHY HUMAN URINE, …
    .
    CDA-2, a URINARY Preparation, Inhibits Lung Cancer Development…
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    .
    4/2009 – CDA-II –
    Journal of Cancer Research & Clinical Oncology
    Comparative proteomics & molecular mechanical analysis in CDA-II induced therapy of LCI-D20 hepatocellular carcinoma model
    .
    .
    1/1/2009 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18761050
    Food & Chemical Toxicology, Elsevier
    CDA-II, a URINARY preparation, induces growth arrest & apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner
    .
    CDA-II (cell differentiation agent II) was a URINARY preparation, isolated from HEALTHY HUMAN URINE. We determined the anticancer activity of CDA-II using human acute myeloid leukemia
    Food & Chemical Toxicology 47: 1, 40-49. Online publication date: 1-Jan-2009.
    1/1/2009 – CDA-II –
    Jian Huang, Min Yang, Hui Liu, Jie Jin. (2009) CDA-II, a URINARY preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner. Food & Chemical Toxicology 47: 1, 40-49. Online publication date: 1-Jan-2009.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101#citedBySection
    2001 – CDA-II –
    Effect of CDA-II, Urinary Preparation on Lipofuscin, Lipid Peroxidation & Antioxidant Systems in Young & Middle-Aged Rat Brain
    Wen-Chuan Lin et al, Am. J. Chin. Med. 29, 91 (2001). DOI: 10.1142/S0192415X01000101
    http:// www. sciencedirect. com/science/article/pii/S0278691508004249
    2012 – CDA-2 –
    PloS one
    CDA-2, a URINARY Preparation, Inhibits Lung Cancer Development through the Suppression of NF-kappaB Activation in Myeloid Cell
    http:// www. plosone. org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117
    2012 – CDA-II – China
    Biochemical and …, Elsevier
    http:// www. ncbi. nlm. nih. gov/m/pubmed/22627135
    DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    .
    8/1/2008 – CDA-2 –
    Jian HUANG, Min YANG, Hui LIU, Jie JIN. (2008) Human URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner 1. Acta Pharmacologica Sinica 29: 8, 951-964. Online publication date: 1-Aug-2008.
    2008 – CDA-2 –
    6. Huang J, Yang M, Liu H, Jin J (2008) Human URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin 29: 951–964.
    2008 – CDA-2 –
    Jian HUANG, Min YANG, Hui LIU, Jie JIN. (2008) Human URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner 1. Acta Pharmacologica Sinica 29: 8, 951-964. Online publication date: 1-Aug-2008.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101#citedBySection
    2008 – CDA-II –
    Effect of CDA-II, URINARY Preparation on Lipofuscin, Lipid Peroxidation & Antioxidant Systems in Young & Middle-Aged Rat Brain
    Wen-Chuan Lin et al, Am. J. Chin. Med. 29, 91 (2001). DOI: 10.1142/S0192415X01000101
    Original Article
    Acta Pharmacologica Sinica (2008) 29, 951–964; doi:10.1111/j.1745-7254.2008.00826.x
    Antitumor Pharmacology
    .
    HUMAN URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner
    .
    Received 9 December 2007; Accepted 19 May 2008.
    .
    The aim of this study was to investigate the antitumoral activity of HUMAN URINE extract against myelodysplastic syndrome (MDS)-derived MUTZ-1 cells in vitro & in vivo.
    .
    The MDS–refractory anemia with excess of blasts (RAEB)-derived MUTZ-1 cell line was used to examine the effects of a HUMAN URINE preparation, CDA-2, …
    .
    We found that CDA-2 could induce growth arrest…
    .
    Our results demonstrate the presence of active components in the HUMINE URINE extract…
    2006 – CDA-II –
    Lin WC, Liao YC, Liau MC, Lii CK, Sheen LY. Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B(1)-induced oxidative stress & DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol 2006; 44: 546–51.
    2005 – HUMAN URINE EXTRACT –
    Yao CJ, Lai GM, Chan CF, Yang YY, Liu FC, Chuang SE. Differentiation of pheochromocytoma PC12 cells induced by HUMAN URINE EXTRACT & the involvement of the extracellular signal-regulated kinase signaling pathway. J Altern Complement Med 2005; 11: 903–8.
    http:// www. plosone. org/article/findcited/6394083
    .
    http:// www. nature. com/aps/journal/v29/n8/full/aps2008115a.html
    2006 – CDA-II –
    4. Lin WC, Liao YC, Liau MC, Lii CK, Sheen LY (2006) Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B(1)-induced oxidative stress & DNA damage in primary cultured rat hepatocytes. Food Chem Toxicol 44: 546–551.
    http:// www. plosone. org/article/findcited/6394081
    .
    .
    4/1/2006 – CDA-II –
    W.C. Lin, Y.C. Liao, M.C. Liau, C.K. Lii, L.Y. Sheen. (2006) Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B1-induced oxidative stress & DNA damage in primary cultured rat hepatocytes. Food & Chemical Toxicology 44: 4, 546-551. Online publication date: 1-Apr-2006.
    .
    .
    2006 – CDA-2 –
    6. Huang J, Yang M, Liu H, Jin J (2008) HUMAN URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. Acta Pharmacol Sin 29: 951–964.
    http://www.plosone.org/article/findcited/6394081
    .
    .
    10/1/2005 – HUMAN URINE Extract –
    Chih-Jung Yao, Gi-Ming Lai, Chin-Feng Chan, Ya-Yu Yang, Frank C. Liu, Shuang-En Chuang. (2005) Differentiation of Pheochromocytoma PC12 Cells Induced by HUMAN URINE Extract & the Involvement of the Extracellular Signal–Regulated Kinase Signaling Pathway. The Journal of Alternative & Complementary Medicine 11:5, 903-908. Online publication date: 1-Oct-2005.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101#citedBySection
    .
    http:// online. liebertpub. com/doi/abs/10.1089/acm.2005.11.903
    .
    .
    6/1/2005 – CDA-II – China
    Chinese Journal of Clinical Oncology, Springer
    Anti-tumor effect of CDA-II on a human glioma cell
    CDA-II has a significant anti-tumor effect on the human glioma SWO-38 cells, and is a potential and natural anti-glioma therapeutic reagent.
    Chinese Journal of Clinical Oncology 2: 3, 679-684. Online publication date: 1-Jun-2005.
    2005 – CDA-II –
    Hongyan Wang, Xueyun Zhong, Frank C. Liu, Yanfang Qin. (2005) Anti-tumor effect of CDA-II on a human glioma cell. Chinese Journal of Clinical Oncology 2:3, 679-684. Online publication date: 1-Jun-2005.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101#citedBySection
    1986 – ANTINEOPLASTONS – SRB
    7. BURZYNSKI SR. ANTINEOPLASTONS: History of the research (1). Drugs Exp Clin Res. 1986; 12: 1–9.
    2003 – A10 & AS2-1 – SRB
    9. BURZYNSKI SR, Lewy RI, Weaver RA, et al. Phase II study of ANTINEOPLASTON A10 & AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R&D. 2003; 4: 91–101.
    2003 – CDA-II – Japan
    11. Liu JW, Tang Y, Shen Y, et al. Apoptosis threshold of hepatoma cell lines induced by As2O3 & CDA-II. Chin J Exp Surg. 2003; 20: 116–117.
    2003 – CDA-II –
    12. Liu JW, Tang Y, Shen Y, et al. Synergistic effect of CELL DIFFERENTIATION AGENT II & arsenic trioxide on induction of cell cycle & apoptosis in hepatotumor cells. World J Gastroentero. 2003; 9:65–68.
    2001 – CDA-II –
    13. Lin WC, Wu YW, Lai TY, et al. Effect of CDA-II, URINARY preparation, on lipofuscin, lipid peroxidation & antioxidant systems in young & middle-aged rat brain. Am J Chin Med. 2001; 29: 91–99.
    http:// link. springer. com/article/10.1007%2FBF02739731
    .
    http:// www. springerlink. com/content/vq43t88675366262
    .
    http:// link. springer. com/article/10.1007%2FBF02739731?LI=true
    1986 – ANTINEOPLASTONS – SRB
    7. BURZYNSKI SR. ANTINEOPLASTONS: History of the research (1). Drugs Exp Clin Res. 1986; 12:1–9.
    2003 – A10 & AS2-1 – SRB
    9. BURZYNSKI SR, Lewy RI, Weaver RA, et al. Phase II study of ANTINEOPLASTON A10 & AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R&D. 2003; 4: 91–101.
    http:// pubget. com/paper/pgtmp_4d814ecf720d4d7eba6c1fa3cb1752a0/Anti_tumor_effect_of_CDA_II_on_a_human_glioma_cell
    .
    http:// link. springer. com/article/10.1007%2FBF02739731
    .
    http:// www. springerlink. com/content/vq43t88675366262
    .
    .
    6/2005 – CDA-II – China
    Chinese Journal of Clinical Oncology
    Anti-tumor effect of CDA-II on a human glioma cell
    To examine the effect of uroacitide (CDA-II ), an extraction product from NORMAL HUMAN URINE, …
    1999 – CDA-II –
    2. Liao MC. A clever anticancer drug CDA-H. Taipei: ShiMao publisher. 1999; 149–161.
    1986 – ANTINEOPLASTONS – SRB
    http:// www. ncbi. nlm. nih. gov/m/pubmed/3527634
    1986 – ANTINEOPLASTONS – SRB
    7. BURZYNSKI SR. ANTINEOPLASTONS: History of the research (1). Drugs Exp Clin Res. 1986; 12:1–9.
    2002 – CDA-II – China
    8. Feng PY, Li Q, Wang ZJ, et al. The clinic study of CDA-H improve life quality of terminal malignancy patient. China Cancer. 2002; 11:108–200.
    2003 – A10 & AS2-1 – SRB
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12718563
    2003 – A10 & AS2-1 – SRB
    9. BURZYNSKI SR, Lewy RI, Weaver RA, et al. Phase II study of ANTINEOPLASTON A10 & AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R&D. 2003; 4: 91–101.
    http:// adisonline. com/drugsrd/pages/articleviewer.aspx?mobile=0&year=2003&issue=04020&article=00002&type=Abstract&desktopMode=true
    2003 – CDA-II – China
    11. Liu JW, Tang Y, Shen Y, et al. Apoptosis threshold of hepatoma cell lines induced by As2O3 & CDA-II. Chin J Exp Surg. 2003; 20: 116–117.
    http:// file. lw23. com/c/c7/c72/c72a0e97-48c5-4632-ad5e-247dcdf4e84e.pdf
    2001 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/11321484
    2001 – CDA-II –
    13. Lin WC, Wu YW, Lai TY, et al. Effect of CDA-II, URINARY preparation, on lipofuscin, lipid peroxidation & antioxidant systems in young & middle-aged rat brain. Am J Chin Med. 2001; 29: 91–99.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101
    2003 – CDA-II – China
    Liu JW, Tang Y, Shen Y, et al. Apoptosis threshold of hepatoma cell lines induced by As2O3 & CDA-II. Chin J Exp Surg. 2003; 20: 116–117.
    http:// file. lw23. com/c/c7/c72/c72a0e97-48c5-4632-ad5e-247dcdf4e84e.pdf
    1/1/2001 – CDA-II – Taiwan, ROC
    http://www.ncbi.nlm.nih.gov/m/pubmed/11321484
    Effect of CDA-II, URINARY Preparation on Lipofuscin, Lipid Peroxidation & Antioxidant Systems in Young & Middle-Aged Rat Brain
    Wen-Chuan Lin et al, Am. J. Chin. Med. 29, 91 (2001). DOI: 10.1142/S0192415X01000101
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101
    1/1/2003 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12943172
    Wen-Chuan Lin et al, Am. J. Chin. Med. 31, 415 (2003). DOI: 10.1142/S0192415X0300103X
    .
    Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration & Its Related Enzyme Activities in Primary Rat Hepatocytes
    Wen-Chuan Lin, Yuan-Chang Liao, Ming-Cheng Liau, Lee-Yan Sheen. (2003) Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration & Its Related Enzyme Activities in Primary Rat Hepatocytes. The American Journal of Chinese Medicine 31: 03, 415-423. Online publication date: 1-Jan-2003.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    4/1/2006 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16229933
    W.C. Lin, Y.C. Liao, M.C. Liau, C.K. Lii, L.Y. Sheen. (2006) Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B1-induced oxidative stress & DNA damage in primary cultured rat hepatocytes. Food & Chemical Toxicology 44: 4, 546-551. Online publication date: 1-Apr-2006.
    http:// www. sciencedirect. com/science/article/pii/S0278691505002875
    1/1/2003 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12943172
    Wen-Chuan Lin, Yuan-Chang Liao, Ming-Cheng Liau, Lee-Yan Sheen. (2003) Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration & Its Related Enzyme Activities in Primary Rat Hepatocytes. The American Journal of Chinese Medicine 31: 03, 415-423. Online publication date: 1-Jan-2003.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101#citedBySection
    .
    Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration & Its Related Enzyme Activities in Primary Rat
    Hepatocytes.
    .
    This study investigated the effects of various concentrations and incubation time intervals of CDA-II (cell differentiation agent: a preparation of HUMAN URINE) on cell viability, …
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    6/8/2012 – CDA-II – China / USA
    Biochemical & Biophysical Research Communications 422: 3, 522-526. Online publication date: 1-Jun-2012.
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    4/1/2006 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16229933
    W.C. Lin, Y.C. Liao, M.C. Liau, C.K. Lii, L.Y. Sheen. (2006) Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B1-induced oxidative stress & DNA damage in primary cultured rat hepatocytes. Food & Chemical Toxicology 44: 4, 546-551. Online publication date: 1-Apr-2006.
    http:// www. sciencedirect. com/science/article/pii/S0278691505002875
    .
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    .
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X?prevSearch=%22CDA-II%22&searchHistoryKey=
    .
    http:// openagricola. nal. usda. gov/Record/IND43793893
    2000 – CDA-II –
    G. M. Lai, HUMAN URINE extracts (CDA-II) as a novel anticancer agent in the aspects of induction of differentiation & apoptosis, antitumorigenesis, chemoprevention & reversal of drug resistance, NHRI Conf. New Drug Dev. Chin. Med. (2000) p. 12.
    1988 – A5 – SRB
    M. C. Liau, S. S. Lee & S. R. BURZYNSKI, Advances in Experimental & Clinical Chemotherapy, Differentiation-inducing components of ANTINEOPLASTON A5, ed. H. P. Kuemmerle (Ecomed Verlagsgesellschaft, Munich, 1988) pp. 9–25.
    https:// data. epo. org/publication-server/pdf-document?PN=EP0680756%20EP%200680756&iDocId=4830495&iepatch=.pdf
    1990 – SRB
    M. C. Liau & S. R. BURZYNSKI, Int. J. Tissue React. 7 (suppl.), 1 (1990).
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X?prevSearch=%22CDA-II%22&searchHistoryKey=
    .
    .
    1/1/2003 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12943172
    Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration & Its Related Enzyme Activities in Primary Rat Hepatocytes
    The American Journal of Chinese Medicine 31: 03, 415-423. Online publication date: 1-Jan-2003.
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    6/8/2012 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/22627135
    Zirong Chen, Guorong Jin, Shuibin Lin, Xiumei Lin, Yumei Gu, Yujuan Zhu, Chengbin Hu, Qingjiong Zhang, Lizi Wu, Huangxuan Shen. (2012) DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation. Biochemical & Biophysical Research Communications 422: 3, 522-526. Online publication date: 1-Jun-2012.
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    4/1/2006 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16229933
    W.C. Lin, Y.C. Liao, M.C. Liau, C.K. Lii, L.Y. Sheen. (2006) Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B1-induced oxidative stress & DNA damage in primary cultured rat hepatocytes. Food & Chemical Toxicology 44: 4, 546-551. Online publication date: 1-Apr-2006.
    http:// www. sciencedirect. com/science/article/pii/S0278691505002875
    .
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    1986 – SRB
    http:// www. ncbi. nlm. nih. gov/m/pubmed/3743383
    23. Liau MC, BURZYNSKI SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res. 1986; 12 (Supp1. 1): 77-86
    1992 – ANTINEOPLASTON – Japan
    31. Liau M C, Luong Y, Liau CP, eta1. Prevention of drug induced DNA hypermethylation by ANTINEOPLASTON components. Intl J Exp Clin Chem other. 1992; 5: 19-27
    https:// data. epo. org/publication-server/pdf-document?PN=EP0680756%20EP%200680756&iDocId=4830495&iepatch=.pdf
    1990 – A5 – SRB
    32. Liau M C, Lee SS, BURZYNSKI SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by ANTINEOPLASTON A5. Intl J Tiss React 1990; 12 (Supp1. 1): 27-36
    https:// data. epo. org/publication-server/pdf-document?PN=EP0680756%20EP%200680756&iDocId=4830495&iepatch=.pdf
    1987 – SRB
    http:// www. ncbi. nlm. nih. gov/m/pubmed/3569019
    35. Liau M C, Szopa M, BURZYNSKI, eta1. Chemosurveilance: a novel concept of natural defense mechanism against cancer. Drugs Exp Clin Res. 1987; 13 (Supp1. 1: 77-82
    2008 – CDA-2 – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18664328
    Acta Pharmacologica Sinica, Wiley Online Library
    HUMAN URINE extract CDA‐2 induces apoptosis of myelodysplastic syndrome‐derived MUTZ‐1 cells through the PI3K/Akt signaling pathway in a caspase‐3‐ …
    J Huang, M Yang, H Liu, J Jin
    http:// www. nature. com/aps/journal/v29/n8/full/aps2008115a.html
    .
    http:// www. nature. com/aps/journal/v29/n8/pdf/aps2008115a.pdf
    .
    http:// onlinelibrary. wiley. com/doi/10.1111/j.1745-7254.2008.00826.x/abstract
    4/2009 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18853186
    Journal of Cancer Research & Clinical Oncology, Springer
    Comparative proteomics & molecular mechanical analysis in CDA-II induced therapy of LCI-D20 hepatocellular carcinoma model
    H Fan, H Liu, C Zhang, D Gao, Q Xue, J Chen…
    http:// link. springer. com/article/10.1007%2Fs00432-008-0493-0
    .
    http:// link. springer. com/article/10.1007%2Fs00432-008-0493-0?LI=true
    1/2009 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18761050
    Food & Chemical Toxicology, Elsevier
    CDA-II, a URINARY preparation, induces growth arrest & apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent …
    J Huang, M Yang, H Liu, J Jin
    http:// www. sciencedirect. com/science/journal/02786915
    .
    http:// www. sciencedirect. com/science/article/pii/S0278691508004249
    2012 – CDA-2 – China
    PloS one
    CDA-2, a URINARY Preparation, Inhibits Lung Cancer Development through the Suppression of NF-kappaB Activation in Myeloid Cell
    X Wang, CM Jiang, HY Wan, JL Wu, WQ Quan, R Bals…
    http:// www. plosone. org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117
    6/8/2012 – CDA-II – China / USA
    http:// www. ncbi. nlm. nih. gov/m/pubmed/22627135
    Biochemical and Biophysical Research Communications, Elsevier
    DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation
    Z Chen, G Jin, S Lin, X Lin, Y Gu, Y Zhu, C Hu…
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    6/2002 – CDA-
    Feng PY, Li Q, Wang ZJ, et al. The clinic study of CDA-H improve life quality of terminal malignancy patient. China Cancer. 2002; 11: 108–200.
    http:// d. g. wanfangdata. com. cn/ExternalResource-zgzllc-e200503014%5e8.aspx
    2001 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/11321484
    Lin WC, Wu YW, Lai TY, et al. Effect of CDA-II, URINARY preparation, on lipofuscin, lipid peroxidation & antioxidant systems in young & middle-aged rat brain. Am J Chin Med. 2001; 29: 91–99.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101
    2001 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/11321484
    Wen-Chuan Lin et al, Am. J. Chin. Med. 29, 91 (2001). DOI: 10.1142/S0192415X01000101
    Effect of CDA-II, URINARY Preparation on Lipofuscin, Lipid Peroxidation & Antioxidant Systems in Young & Middle-Aged Rat Brain
    .
    Accepted: 7 August 2000
    .
    We examined the effects of CDA-ll, a preparation of HUMAN URINE, …
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101
    1/2003 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12508353
    World Journal of Gastroenterol
    Synergistic effect of CELL DIFFERENTIAL AGENT-II & arsenic trioxide on induction of cell cycle arrest & apoptosis in hepatoma cells
    JW Liu, Y Tang, Y Shen, XY Zhong
    http:// www. wjgnet. com/1007-9327/9/65.asp
    .
    http:// www. wjgnet. com/1007-9327/full/v9/i1/65.htm
    2005 – HUMAN URINE extract – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16296925
    Journal of Alternative & Complementary Medicine
    Differentiation of pheochromocytoma PC12 cells induced by HUMAN URINE extract & the involvement of the extracellular signal-regulated kinase signaling pathway
    CJ Yao, GM Lai, CF Chan, YY Yang…
    http:// online. liebertpub. com/doi/abs/10.1089/acm.2005.11.903
    .
    http:// ir. nhri. org. tw/handle/3990099045/2796
    8/2008 – CDA-2 – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18664328
    Acta Pharmacologica Sinica, Wiley Online Library
    HUMAN URINE extract CDA‐2 induces apoptosis of myelodysplastic syndrome‐derived MUTZ‐1 cells through the PI3K/Akt signaling pathway in a caspase‐3‐ …
    J Huang, M Yang, H Liu, J Jin
    http:// onlinelibrary. wiley. com/doi/10.1111/j.1745-7254.2008.00826.x/abstract
    .
    .
    2003 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12943172
    The American Journal of Chinese Medicine, An International Journal of Comparative Medicine East and West, World Scientific
    Effect of CDA-II on cell viability, lipid peroxidation, glutathione concentration & its related enzyme activities in primary rat hepatocytes
    WC Lin, YC Liao, MC Liau, LY Sheen
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X0300103X
    1/2009 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18761050
    Food and Chemical Toxicology, Elsevier
    CDA-II, a URINARY preparation, induces growth arrest & apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent …
    J Huang, M Yang, H Liu, J Jin -
    http:// www. sciencedirect. com/science/article/pii/S0278691508004249
    6/2005 – CDA-II – China
    Chinese Journal of Clinical Oncology, Springer
    Anti-tumor effect of CDA-II on a human glioma cell
    H Wang, X Zhong, FC Liu, Y Qin
    http:// link. springer. com/article/10.1007%2FBF02739731?LI=true
    Cited by :
    1/1/2009 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18761050
    Jian Huang, Min Yang, Hui Liu, Jie Jin. (2009) CDA-II, a URINARY preparation, induces growth arrest & apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner. Food & Chemical Toxicology 47: 1, 40-49. Online publication date: 1-Jan-2009.
    http:// www. sciencedirect. com/science/article/pii/S0278691508004249
    8/1/2008 – CDA-2 – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/18664328
    Jian HUANG, Min YANG, Hui LIU, Jie JIN. (2008) HUMAN URINE extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner 1. Acta Pharmacologica Sinica 29: 8, 951-964. Online publication date: 1-Aug-2008.
    10/1/2005 – HUMAN URINE Extract – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16296925
    Chih-Jung Yao, Gi-Ming Lai, Chin-Feng Chan, Ya-Yu Yang, Frank C. Liu, Shuang-En Chuang. (2005) Differentiation of Pheochromocytoma PC12 Cells Induced by HUMAN URINE Extract & the Involvement of the Extracellular Signal–Regulated Kinase Signaling Pathway. The Journal of Alternative & Complementary Medicine 11: 5, 903-908. Online publication date: 1-Oct-2005.
    6/1/2005 – CDA-II – China
    Hongyan Wang, Xueyun Zhong, Frank C. Liu, Yanfang Qin. (2005) Anti-tumor effect of CDA-II on a human glioma cell. Chinese Journal of Clinical Oncology 2: 3, 679-684. Online publication date: 1-Jun-2005.
    http:// link. springer. com/article/10.1007%2FBF02739731
    .
    http:// link. springer. com/article/10.1007%2FBF02739731?LI=true
    1/1/2003 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/12943172
    Wen-Chuan Lin, Yuan-Chang Liao, Ming-Cheng Liau, Lee-Yan Sheen. (2003) Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration & Its Related Enzyme Activities in Primary Rat Hepatocytes. The American Journal of Chinese Medicine 31: 03, 415-423. Online publication date: 1-Jan-2003.
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101?prevSearch=%22CDA-II%22&searchHistoryKey=
    .
    http:// www. worldscientific. com/doi/abs/10.1142/S0192415X01000101#citedBySection
    4/2006 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16229933
    Food and Chemical Toxicology, Elsevier
    Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B 1-induced oxidative stress and DNA damage in primary cultured rat hepatocytes
    WC Lin, YC Liao, MC Liau, CK Lii, LY Sheen
    http:// www. sciencedirect. com/science/article/pii/S0278691505002875
    6/8/2012 – CDA-II – China/USA
    http:// www. ncbi. nlm. nih. gov/m/pubmed/22627135
    Biochemical & Biophysical Research Communications, Elsevier
    DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation
    Z Chen, G Jin, S Lin, X Lin, Y Gu, Y Zhu, C Hu…
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    .
    2000 – CDA-II – China
    G. M. Lai, HUMINE URINE extracts (CDA-II) as a novel anticancer agent in the aspects of induction of differentiation & apoptosis, antitumorigenesis, chemoprevention & reversal of drug resistance, NHRI Conf. New Drug Dev. Chin. Med. (2000) p. 12.
    4/2006 – CDA-II – Taiwan, ROC
    http:// www. ncbi. nlm. nih. gov/m/pubmed/16229933
    Food & Chemical Toxicology, Elsevier
    Inhibitory effect of CDA-II, a URINARY preparation, on aflatoxin B 1-induced oxidative stress & DNA damage in primary cultured rat hepatocytes
    WC Lin, YC Liao, MC Liau, CK Lii, LY Sheen
    http:// www. sciencedirect. com/science/article/pii/S0278691505002875
    6/8/2012 – CDA-II – China
    http:// www. ncbi. nlm. nih. gov/m/pubmed/22627135
    Biochemical & Biophysical Research Communications, Elsevier
    DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation
    Z Chen, G Jin, S Lin, X Lin, Y Gu, Y Zhu, C Hu…
    http:// www. sciencedirect. com/science/article/pii/S0006291X1200945X
    .
    .
    1999 – CDA-II – Taiwan, ROC
    Liao MC. A clever anticancer drug CDA-H. Taipei: ShiMao publisher. 1999; 149–161.
    http:// d. g. wanfangdata. com. cn/ExternalResource-zgzllc-e200503014%5e2.aspx
    .
    .
    1990 – SRB
    M. C. Liau & S. R. BURZYNSKI, Int. J. Tissue React. 7 (suppl.), 1 (1990).
    .
    .
    1988 – A5 – SRB
    M. C. Liau, S. S. Lee & S. R. BURZYNSKI, Advances in Experimental &Clinical Chemotherapy, Differentiation-inducing components of ANTINEOPLASTON A5, ed. H. P. Kuemmerle (Ecomed Verlagsgesellschaft, Munich, 1988) pp. 9–25.
    https:// data. epo. org/publication-server/pdf-document?PN=EP0680756%20EP%200680756&iDocId=4830495&iepatch=.pdf
    .
    MarkyLMark, I you want me to believe you’re “STOOPID,” you’ve already succeeded!!
    .
    MarkyLMark, who said they could cure all types of cancers / diseases?
    1. GOD
    2. Jesus Christ
    3. Allah
    4. Buddha
    5. The Pope
    6. Benny Hin
    7. Satin
    8. Ba’al
    9. Baalzebub
    10. MarkyLMark